Bora Pharmaceuticals and Onconic Therapeutics announced a manufacturing agreement intended to support U.S. clinical development of JAQBO tablets. The news is operational in nature with no disclosed financial terms or efficacy/regulatory milestones, suggesting limited near-term impact.
Bora Pharmaceuticals and Onconic Therapeutics announced a manufacturing agreement intended to support U.S. clinical development of JAQBO tablets. The news is operational in nature with no disclosed financial terms or efficacy/regulatory milestones, suggesting limited near-term impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.08
